Literature DB >> 2292659

Increase by naloxone of arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in obese men.

V Coiro1, L Capretti, G Speroni, A Castelli, L Bianconi, U Cavazzini, A Marcato, R Volpi, P Chiodera.   

Abstract

The present study was carried out to establish whether the low arginine vasopressin (AVP) and oxytocin (OT) responses to insulin-induced hypoglycemia observed in obese men was due to alteration of the opioid control of posterior pituitary function. For this purpose, the AVP and OT releasing effect of insulin (0.15 IU/kg bw)--induced hypoglycemia was tested in eight normal weight men and in 10 age-matched obese subjects, without and with the previous treatment with the specific opioid receptor antagonist naloxone (3 mg in an iv bolus). In a control study, naloxone was given alone to the same subjects. Obese men showed similar basal glucose, AVP and OT levels, which remained unmodified after treatment with naloxone alone. Insulin induced a similar decrement of blood glucose levels in all subjects, with a nadir at 30 min. Plasma levels of AVP and OT rose strikingly in normal and obese subjects with mean peak responses at 30 min for AVP and at 45 min for OT. However, both AVP and OT responses were significantly lower in obese than in control subjects. Pretreatment with naloxone did not modify the AVP and OT responses to hypoglycemia in normal weight subjects, whereas it significantly enhanced both hormonal responses in obese subjects. In the presence of naloxone normal controls and obese subjects showed similar responses of both AVP and OT to hypoglycemia. These data indicate that an abnormal activity of endogenous opioids might account for the hypothalamic posterior pituitary dysfunction, which is responsible for the low AVP and OT responses to insulin-induced hypoglycemia in obesity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292659     DOI: 10.1007/BF03349617

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  52 in total

1.  Relationship between plasma and cerebrospinal fluid insulin levels of dogs.

Authors:  S C Woods; D Porte
Journal:  Am J Physiol       Date:  1977-10

Review 2.  Neuroendocrine control of blood tonicity and volume.

Authors:  H S Chowdrey; S L Lightman
Journal:  Baillieres Clin Endocrinol Metab       Date:  1989-08

3.  Pharmacological doses of oxytocin affect plasma hormone levels modulating glucose homeostasis in normal man.

Authors:  G Paolisso; S Sgambato; N Passariello; R Torella; D Giugliano; S Mignano; M Varricchio; F D'Onofrio
Journal:  Horm Res       Date:  1988

Review 4.  Central nervous system mediators of vasopressin release.

Authors:  A H Sklar; R W Schrier
Journal:  Physiol Rev       Date:  1983-10       Impact factor: 37.312

5.  Endogenous opiates and energy balance.

Authors:  A Mandenoff; F Fumeron; M Apfelbaum; D L Margules
Journal:  Science       Date:  1982-03-19       Impact factor: 47.728

6.  Insulin binding sites localized to nerve terminals in rat median eminence and arcuate nucleus.

Authors:  M van Houten; B I Posner; B M Kopriwa; J R Brawer
Journal:  Science       Date:  1980-03-07       Impact factor: 47.728

7.  Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

Authors:  G Plewe; U Schneider; U Krause; J Beyer
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

8.  beta-Endorphin is associated with overeating in genetically obese mice (ob/ob) and rats (fa/fa).

Authors:  D L Margules; B Moisset; M J Lewis; H Shibuya; C B Pert
Journal:  Science       Date:  1978-12-01       Impact factor: 47.728

Review 9.  Endogenous opioid peptides and hypothalamic neuroendocrine neurones.

Authors:  R J Bicknell
Journal:  J Endocrinol       Date:  1985-12       Impact factor: 4.286

10.  Plasma B-endorphin resistance to dexamethasone suppression in obese patients.

Authors:  F Facchinetti; C Giovannini; F Petraglia; C Barletta; G Comitini; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1988-02       Impact factor: 4.256

View more
  2 in total

1.  The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.

Authors:  S Balon-Perin; J Kolanowski; A Berbinschi; P Franchimont; J M Ketelslegers
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

Review 2.  Metabolic Effects of Oxytocin.

Authors:  Shana E McCormack; James E Blevins; Elizabeth A Lawson
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.